Background: Epidemiological studies evaluating the association of vitamin B 6 , vitamin B 12 and methionine with breast cancer risk have produced inconsistent results.
Breast cancer is the most frequently diagnosed types of cancer and the leading cause of cancer death among women worldwide, accounting for 23% of the total cancer cases and 14% of the cancer deaths, and about half the breast cancer cases and 60% of the deaths are estimated to occur in economically developing countries (Jemal et al, 2011) . Although incidence rates of breast cancer in some western countries decreased since the beginning of 2000, the incidence rates have been rising in many African and Asian countries (Jemal et al, 2011) . According to the American Cancer Society Guidelines, the nutrition-and physical activity-related advice ) is necessary to reduce the risk of breast cancer (Kushi et al, 2012) . One-carbon metabolism nutrients, such as folate, vitamin B 6 , vitamin B 12 and methionine, may protect against cancer through DNA synthesis and methylation, upholding DNA integrity and regulating gene expression (Ames, 2001; Selhub, 2002) , and pyridoxal 5 0 -phosphate (PLP; the active form of vitamin B 6 ) is involved in almost 100 enzymatic reactions (Bairoch, 2000) . Although no significant effect of folate on breast cancer was found in the previous meta-analysis overall (Larsson et al, 2007) , high alcohol (the known antagonist for these B-vitamins) consumption was shown to be associated with increased risk of breast cancer (Suzuki et al, 2008) . However, results from observational studies on vitamin B 6 , vitamin B 12 and methionine and breast cancer risk are not consistent, and no metaanalysis is available. In addition, folate, vitamin B6 and vitamin B12 act in concert to affect the pathways of one-carbon metabolism (Kim, 2007) , and these nutrient interactions were also proposed (Davis and Uthus, 2004) . Therefore, we conducted a meta-analysis to (1) first assess the breast cancer risk for the highest vs lowest categories of vitamin B 6 , vitamin B 12 and methionine; (2) then evaluate the possible dose-response relationship of vitamin B 6 , vitamin B 12 and methionine with breast cancer risk; (3) investigate the joint association between folate intake with vitamin B 6 , vitamin B 12 and methionine intake, and the risk of breast cancer; (4) evaluate the modification of key covariates to the association of vitamin B 6 , vitamin B 12 and methionine with breast cancer risk; (5) and assess the heterogeneity among studies and publication bias.
MATERIALS AND METHODS
Literature search and selection. We performed a literature search up to 18 June 2013 using the databases of Pubmed and Web of Knowledge, using the following search terms vitamin B 6 or pyridoxal 5'-phosphate (PLP; the active form of vitamin B 6 ), or vitamin B 12 or methionine, and breast cancer without restrictions. Moreover, we reviewed the reference lists from retrieved articles to search for further relevant studies.
Two investigators independently reviewed all identified studies, and studies were included if they met the following criteria: (1) the exposure of interest was vitamin B 6 or PLP, or vitamin B 12 or methionine; (2) the outcome of interest was breast cancer; (3) relative risk (RR) or odds ratio with 95% confidence interval (CI) was provided (we presented all results with RR for simplicity); (4) for dose-response analysis, the number of cases and participants or person-years for each category of vitamin B 6 or PLP, or vitamin B 12 or methionine, must also be provided (or data available to calculate them). If data were duplicated in more than one study, we included the study with the largest number of cases.
Data extraction. The following data were extracted from each study by two investigators: the design type (case-control or prospective study), the first author's last name, publication year, location where the study was performed, sample size and number of cases, variables adjusted for in the analysis, RR estimates with corresponding 95% CI for the highest versus lowest categories of vitamin B 6 , vitamin B 12 and methionine, respectively. The result for dietary intake of these nutrients was extracted if the result for both dietary intake and total intake (dietary intake plus supplement) were provided. To investigate the joint association between folate intake with vitamin B 6 , vitamin B 12 and methionine intake, and risk of breast cancer, RR was extracted from the group with both the highest folate intake and highest vitamin B 6 , vitamin B 12 or methionine intake group versus the group with both the lowest folate intake and lowest vitamin B 6 , vitamin B 12 or methionine intake.
For dose-response analysis, the number of cases and participants (person-years), and RR (95% CI) for each category of vitamin B 6 , vitamin B 12 and methionine were also extracted. The median or mean level of vitamin B 6 , vitamin B 12 and methionine for each category was assigned to the corresponding RR for every study. If the upper boundary of the highest category was not provided, we assumed that the boundary had the same amplitude as the adjacent category (Larsson et al, 2010; Hong et al, 2012) . We extracted the RRs that reflected the greatest degree of control for potential confounders.
Statistical analysis. Pooled measure was calculated as the inverse variance-weighted mean of the logarithm of RR with 95% CI, to assess the strength of association between vitamin B 6 , vitamin B 12 and methionine and the risk of breast cancer. Random-effects model was used to combine study-specific RR (95%CI), which considers both within-study and between-study variation (DerSimonian and Laird, 1986). The I 2 was used to assess heterogeneity, and I 2 values of 0, 25, 50 and 75% represent no, low, moderate and high heterogeneity (Higgins et al, 2003) , respectively. Meta-regression with restricted maximum likelihood estimation was performed to assess the potentially important covariates that might exert substantial impact on between-study heterogeneity (Higgins and Thompson, 2004) . A sensitivity analysis was performed with one study removed at a time to assess whether the results could have been affected markedly by a single study. Publication bias was evaluated using the Egger regression asymmetry test (Egger et al, 1997) .
For dose-response analysis, a two-stage random-effects doseresponse meta-analysis (Orsini et al, 2012) was performed to compute the trend from the correlated log RR estimates across levels of vitamin B 6 , vitamin B 12 and methionine, respectively, taking into account the between-study heterogeneity. In the first stage, a restricted cubic spline model with three knots at the 25th, 50th and 75th percentiles (Harrell et al, 1988) of the levels of vitamin B 6 , vitamin B 12 and methionine was estimated using generalised least-square regression, taking into account the correlation within each set of published RRs (Orsini and Bellocco, 2006) . Then the study-specific estimates were combined using the restricted maximum likelihood method in a multivariate random-effects meta-analysis (Jackson et al, 2010) . A P-value for non-linearity was calculated by testing the null hypothesis that the coefficient of the second spline is equal to 0. All statistical analyses were performed with STATA version 12.0 (Stata Corporation, College Station, TX, USA). All reported probabilities (P-values) were two-sided with Po0.05 considered statistically significant.
RESULTS
Literature search and study characteristics. The search strategy identified 552 articles from Pubmed and 1144 articles from the Web of Knowledge, and 28 articles were reviewed in full after reviewing the abstract. Two studies that assessed the MTHFR C677T (Maruti et al, 2009a,b) , MTR and MTRR (Shrubsole et al, 2006) polymorphisms and breast cancer by intakes of one-carbon metabolism nutrients were further excluded because of duplicate reports from the same study population. Three studies that did not report the risk estimate were also excluded (Potera et al, 1977; Goodman et al, 2001; Schroecksnadel et al, 2003) . Finally, 23 articles (Thorand et al, 1998; Wu et al, 1999a,b; Levi et al, 2001; Shrubsole et al, 2001; Feigelson et al, 2003; Zhang et al, 2003; Zhu et al, 2003; Lajous et al, 2006a; Lajous et al, 2006b; Cho et al, 2007; Kabat et al, 2008; Lin et al, 2008; Xu et al, 2008; Ma et al, 2009a; Ma et al, 2009b; Maruti et al, 2009a,b; Stevens et al, 2010; Chou et al, 2011; Shrubsole et al, 2011; Zhang et al, 2011; Lurie et al, 2012; Bassett et al, 2013; Yang et al, 2013) were included in this meta-analysis. The detailed steps of our literature search are shown in Supplementary Material.
For PLP levels, data from four nested case-control articles with five studies were used, including 2509 breast cancer cases, and all studies were carried out in the United States. For vitamin B 6 intake, data from 14 articles (6 prospective studies and 8 case-control studies) were used, including 14 260 breast cancer cases. Five studies were carried out in the United States, four in China, one in Japan, one in Mexico, one in Switzerland, one in Brazilia and one in Australia. For serum vitamin B 12 levels, data from three nested case-control articles with four studies were used, including 1803 breast cancer cases, and all studies were carried out in the United States. For vitamin B 12 intake, data from 14 articles (7 prospective studies and 7 case-control studies) were used, including 15 783 breast cancer cases. Five studies were carried out in the United States, four in China, one in Japan, one in Mexico, one in France, one in Brazilia and one in Australia. For methionine, data from 13 articles (7 prospective studies and 6 case-control studies) were used, including 17 060 breast cancer cases. Seven studies were carried out in the United States, three China, one in Canada, one in Germany and one in Australia. The detailed characteristics of the studies are shown in Tables 1-3 .
Quantitative synthesis. The main results are summarised in Table 4 (the result by adjustment of selected covariates is not included).
Serum PLP levels and risk of breast cancer. High serum PLP levels vs low levels were significantly associated with the risk of breast cancer (0.80 (0.66-0.98), P ¼ 0.03, I
2 ¼ 0.30%, Figure 1 ). The association was significant for post-menopausal women (0.71 (0.57-0.88), Po0.00, I
2 ¼ 0.00%) but not for pre-menopausal women; however, the difference between the two groups was not significant (P ¼ 0.26). No significant association was found by oestrogen receptor (ER) and progesterone receptor (PR) status. Among the five nested case-control studies, two studies in one article (Wu et al, 1999a,b) only adjusted for age, menopausal status and year of blood donation, and a positive but not significant association of serum PLP levels with the risk of breast cancer was found. Three studies (Zhang et al, 2003; Lin et al, 2008; Lurie et al, 2012) adjusted for the most known risk factors of breast cancer, and a significantly combined effect (Zhang et al, 2003; Lin et al, 2008; Lurie et al, 2012) was found (0.76 (0.62-0.94), P ¼ 0.01,
For dose-response analysis, data from three studies (Zhang et al, 2003; Lin et al, 2008; Lurie et al, 2012) were used, including 2266 breast cancer cases. We found no evidence of statistically significant departure from linearity (P ¼ 0.85). A 100 pmol ml Vitamin B 6 intake and risk of breast cancer. High vitamin B 6 intake vs low intake was not significantly associated with the risk of breast cancer (0.95 (0.83-1.08), P ¼ 0.45, I
2 ¼ 56.2%, Figure 1 ). And no significant association was found in subgroup analysis by study design (prospective and case-control), menopausal status (pre-menopausal and post-menopausal), geographic region where the study was conducted (America and Asia), ER status and PR status. No significant association was found in the subgroup analysis by adjustment (yes or no) of the known risk factors of breast cancer, including alcohol, smoking, BMI, FHBC, reproductive factors (X3), physical activity, energy intake and use of exogenous hormones.
For dose-response analysis, data from eight studies (Lajous et al, 2006a,b; Lin et al, 2008; Ma et al, 2009a; Ma et al, 2009b; Stevens et al, 2010; Zhang et al, 2011; Bassett et al, 2013; Yang et al, 2013) were used, including 9429 breast cancer cases. We found no evidence of statistically significant departure from linearity (P ¼ 0.08). A 1 mg per day increment in vitamin B 6 intake conferred an RR of 0.96 (0.89-1.02, P ¼ 0.19).
Serum vitamin B 12 levels and risk of breast cancer. High serum vitamin B 12 levels vs low levels were not significantly associated with the risk of breast cancer (0.73 (0.44-1.22), P ¼ 0.23, I 2 ¼ 72.5%, Figure 3) , and no significant association was found in the subgroup analysis by menopausal status. Only one study (Lin et al, 2008) provided the association of serum vitamin B 12 levels with the risk of breast cancer by ER status and PR status; thus, the subgroup analysis by ER status and PR status was not conducted. Among the four studies included, one study (Lin et al, 2008) adjusted for the most known risk factors of breast cancer, and women in the highest quintile relative to those in the lowest quintile had multivariate RR of 1.29 (0.92-1.82). The result from the other three studies indicated an obvious protection of serum vitamin B 12 levels on risk of breast cancer (0.61 (0.41-0.92), P ¼ 0.02, I
2 ¼ 22.3%).
For the dose-response analysis, data from two studies (Zhang et al, 2003; Lin et al, 2008) were used, including 1560 breast cancer cases. We found no evidence of statistically significant departure from linearity (P ¼ 0.51). A 100 pmol ml À 1 increment in serum vitamin B 12 levels conferred an RR of 0.99 (0.92-1.08, P ¼ 0.88).
Vitamin B 12 intake and risk of breast cancer. High vitamin B 12 intake vs low intake was not significantly associated with the risk of breast cancer (0.88 (0.77-1.00), P ¼ 0.05, I
2 ¼ 68.9%, Figure 3 ). However, significant association was found in case-control studies (0.74 (0.56-0.98), P ¼ 0.04, I
2 ¼ 74.5%) but not in prospective studies. No significant association was found in other subgroup analysis.
For dose-response analysis, data from nine studies (Lajous et al, 2006a,b; Lin et al, 2008; Ma et al, 2009a; Ma et al, 2009b; Stevens et al, 2010; Chou et al, 2011; Zhang et al, 2011; Bassett et al, 2013; Yang et al, 2013) were used, including 9832 breast cancer cases. We found no evidence of statistically significant departure from linearity (P ¼ 0.14). A 1-mg per day increment in vitamin B 12 intake conferred an RR of 0.98 (0.95-1.00, P ¼ 0.12).
Methionine intake and risk of breast cancer. High methionine intake vs low intake was significantly associated with the risk of breast cancer (0.94 (0.89-0.99), P ¼ 0.03, I
2 ¼ 0.00%, Figure 4 ). Marginally significant association was found in prospective studies (0.94 (0.87-1.00), P ¼ 0.06, I
2 ¼ 0.00%) but not in case-control studies ( Figure 4 ). Significant association was found for postmenopausal women (0.89 (0.82-0.97), P ¼ 0.01, I
2 ¼ 0.01%) but not for pre-menopausal women; however, the difference between the two groups was not significant (P ¼ 0.24). No significant association was found by ER status and PR status. Marginally significant association was found for studies that adjusted for alcohol and use of exogenous hormones, and significant association was also found for studies that adjusted for physical activity, energy intake, BMI, FHBC and reproductive factors (X3).
For dose-response analysis, data from six studies (Feigelson et al, 2003; Xu et al, 2008; Stevens et al, 2010; Zhang et al, 2011; Bassett et al, 2013; Yang et al, 2013) were used, including 10316 breast cancer cases. We found no evidence of statistically significant departure from linearity (P ¼ 0.82). A 1-g per day increment in methionine intake conferred an RR of 0.96 (0.92-1.00, P ¼ 0.05).
Effect of combining folate with vitamin B 6 , vitamin B 12 and methionine on risk of breast cancer. For the joint association between breast cancer risk and folate intake with vitamin B 6 intake, data from four studies (Maruti et al, 2009a,b; Stevens et al, 2010; Chou et al, 2011; Shrubsole et al, 2011) were used, and the risk of breast cancer for the subjects with both highest intake of folate and vitamin B 6 was 0.91 (0.79-1.04), P ¼ 0.17, I 2 ¼ 0.00%. For the joint association between breast cancer risk and folate intake with vitamin B 12 intake, data from three studies (Maruti et al, 2009a,b; Stevens et al, 2010; Shrubsole et al, 2011) were used, and the risk of breast cancer for the subjects with both highest intake of folate and vitamin B 12 was 0.99 (0.77-1.29), P ¼ 0.97, I
2 ¼ 54.2%. For the joint association between breast cancer risk and folate intake with methionine intake, data from four studies (Thorand et al, 1998; Maruti et al, 2009a,b; Stevens et al, 2010; Shrubsole et al, 2011) were used, and the risk of breast cancer for the subjects with both highest intake of folate and methionine was 0.81(0.62-1.05),
Sources of heterogeneity and meta-regression. In order to explore the moderate to high between-study heterogeneity found in several analysis, univariate meta-regression with the covariates of publication year, location where the study was conducted, study design (case-control or prospective), number of cases and degree of adjustments of covariates was performed. Degree of adjustments of covariates ranged from 0 to 9 based on adjustment (yes: 1, no: 0) The two studies were excluded in the final analysis, because RR was not available; the mean concentration of PLP was presented by COMT genotype (HH/HL/LL). 42.48
1.00 (0.88-1.14)
Xu et al ( 1.00 Age, race, FHBC, mammography within 2 years preceding baseline, history of breast biopsy, age at menarche, age at first birth, age at menopause, years of combined oestrogen and progestin postmenopausal hormone use, BMI, physical activity, alcohol intake in the past year and energy intake 1.00 Age at baseline, age at menarche, parity, age at first live birth, educational attainment, physical activity, use of a B vitamin supplement, height, and total daily intakes of energy, vegetable and fat, and menopausal status of the following covariates: alcohol, smoking, BMI, FHBC, reproductive factors (X3), physical activity, energy intake, dietary factors (X2) and use of exogenous hormones. For the analysis between breast cancer risk and dietary vitamin B 12 intake, study design was found contributing significantly to the between-study heterogeneity overall (P ¼ 0.02) and among post-menopausal women (P ¼ 0.02). No significant findings were found in the other analysis.
Sensitivity analysis and publication bias. Sensitivity analysis showed that no individual study had excessive influence on the above mentioned pooled effect. Egger test showed no evidence of significant publication bias for the analysis between breast cancer risk and serum PLP levels (P ¼ 0.10), vitamin B 6 intake (P ¼ 0.14), serum vitamin B 12 levels (P ¼ 0.18), vitamin B 12 intake (P ¼ 0.12) and methionine (P ¼ 0.49). The funnel plots were provided in the Supplementary Material.
DISCUSSION
The findings from this meta-analysis indicated that increased serum PLP levels and dietary methionine intake might be significantly associated with reduced risk of breast cancer, especially for post-menopausal women. No significant association was found between dietary vitamin B 6 intake, serum vitamin B 12 and dietary vitamin B 12 intake and risk of breast cancer. Several biological mechanisms for the inverse relationship of vitamin B 6 , vitamin B 12 and methionine with the development of breast cancer have been proposed. First, vitamin B 6 , B 12 and methionine participate in one-carbon metabolism, which is essential for DNA synthesis, repair and methylation (Ames, 2001) , and vitamins B 6 and B 12 deficiencies also cause high uracil and chromosome breaks (Blount et al, 1997) . Thus, deficiency in these nutrients may interfere with DNA methylation and synthesis, leading to aberrant gene expression and DNA instability, and eventually the development of cancer (Davis and Uthus, 2004) . In addition, low B-group vitamin concentrations are associated with inflammation and higher oxidative stress (Shen et al, 2010) , and antioxidants supplementation with B-group vitamins could enhance antioxidant capacity. Although the mechanism for the stronger association found for post-menopausal women remains unclear, previous meta-analysis also suggested that post-menopausal women are more susceptible to a wide range of dietary factors, including dietary fibre, vitamin A, b-carotene, retinol, vitamin C, calories, fat (Howe et al, 1990; Wu et al, 1999a,b) , folate acid (Larsson et al, 2007) , fatty acids (Saadatian-Elahi et al, 2004) , and coffee and caffeine (Jiang et al, 2013) , regarding their association with breast cancer risk. In addition, although these nutrient interactions were also proposed, no apparent joint association with high folate intake was found in this meta-analysis, which is consistent with the previous study .
As a meta-analysis of published observational studies, our findings have several limitations. First, disparate results were found on dietary vitamin B 6 intake and PLP with the risk of breast cancer. The multivariable Pearson's correlation coefficients between plasma levels of vitamin B 6 and vitamin B 12 , and the average intakes of vitamin B 6 and vitamin B 12 from food was 0.25 and 0.08, respectively (Zhang et al, 2003) . In this respect, the serum biomarker of vitamin B 6 (PLP) and vitamin B 12 was able to examine these associations with higher precision. Disparate results between serum biomarkers of vitamins and dietary intake of vitamins and breast cancer risk were also found in other metaanalysis, such as vitamin B 6 (Larsson et al, 2007) and vitamin D (Chen et al, 2010) . Second, a meta-analysis of observational studies is susceptible to potential bias inherent in the original studies, especially for case-control studies. Stronger association was found Figure 1 . The multivariate-adjusted risk of breast cancer for the highest vs lowest categories of serum PLP levels and dietary vitamin B 6 intake in random-effects model. The size of the grey box is positively proportional to the weight assigned to each study, which is inversely proportional to the s.e. of the RR, and horizontal lines represent the 95% CIs.
in the combined results from case-control studies in this metaanalysis. Overstated association could be expected from the casecontrol studies because of recall or selection bias, and early symptoms in patients may have resulted in a change in dietary habits. Thus, the results from prospective studies might provide a more robust estimation of the associations.
Third, although we extracted the RRs that reflected the greatest degree of control for potential confounders, the extent to which they were adjusted and the possibility that the observed association was due to unmeasured or residual confounding should be considered. Furthermore, vitamin B 6 intake tends to be associated with healthy behaviours that may be protective against breast cancer (Larsson et al, 2010) . However, significant association was also found (0.76 (0.62-0.94)) on serum PLP levels and breast cancer risk for the three studies that adjusted for the most known risk factors of breast cancer. In addition, no significant interactions were found between MTHFR and MTR polymorphisms and B vitamins (Ma et al, 2009a; Ma et al, 2009b) , and result from the study by Lin et al (2008) suggested a much stronger and significant association of serum PLP and vitamin B 12 levels with breast cancer risk for never user of post-menopausal hormones. However, the limited data in the reported articles precluded a more robust assessment of the association by the above-mentioned risk factors.
Fourth, although significant association of PLP levels and methionine intake with risk of breast cancer was found among post-menopausal women, while not among pre-menopausal women, the difference between the two groups was not significant, and the apparent differences could simply be by chance, considering relatively small number of studies included, especially for pre-menopausal women. And subgroup analysis by tumour stage (in situ or invasive) were not conducted because of limited data availability (Zhang et al, 2003; Chou et al, 2011) . Fifth, between-study heterogeneity was found in some analysis in this meta-analysis, but the between-study heterogeneity was not successfully explained by the subgroup analysis and metaregression. However, other genetic and environment variables, as well as their possible interaction, non-comparable measurement of nutrients and variation of the covariates and so on, may well be potential contributors to this disease-effect unconformity (Higgins et al, 2003) . In this respect, the lack of relevant study-level covariates in the reported articles precluded a more robust assessment of sources of this heterogeneity. Finally, although no significant publication bias was detected in this meta-analysis, validity of publication bias test should be questioned because of small number of studies included (Sterne et al, 2000) , especially for PLP and serum vitamin B 12 . In summary, results from this meta-analysis suggested that serum PLP levels and dietary methionine intake might be significantly associated with reduced risk of breast cancer, especially for post-menopausal women. The finding needs to be confirmed further by a well-conducted randomised trial. Figure 4. The multivariate-adjusted risk of breast cancer for the highest vs lowest categories of dietary methionine intake in random-effects model. The size of the grey box is positively proportional to the weight assigned to each study, which is inversely proportional to the s.e. of the RR, and horizontal lines represent the 95% CIs.
